TCA
DGX icon

Trifecta Capital Advisors’s Quest Diagnostics DGX Stock Holding History

Trifecta Capital Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212 Buy
+1
New +$196 ﹤0.01% 464

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Trifecta Capital Advisors's DGX Position: Q2 2026 in Review

Trifecta Capital Advisors opened a new position in Quest Diagnostics (DGX) in Q2 2026: 1 share worth $212. The stake represents ﹤0.01% of the portfolio and ranks #464 among its holdings.

1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Trifecta Capital Advisors held 1 share of Quest Diagnostics worth $212 as of Q2 2026.
  • Quest Diagnostics was a new Trifecta Capital Advisors position in Q2 2026.
  • Quest Diagnostics made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #464 holding.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.